Cargando…
Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model
Ovarian cancer (OC) is one of the most lethal solid tumors with poor prognosis. In 2017, two chimeric antigen receptor-T (CAR-T) cell drugs were approved by the U.S. Food and Drug Administration (FDA), and continuously optimized CAR-T cells therapy might be the novel hope for OC patient. EpCAM are k...
Autores principales: | FU, Juan, SHANG, Yuhong, QIAN, Zhang, HOU, Jinping, YAN, Feng, LIU, Guodi, DEHUA, Li, TIAN, Xiaoli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Veterinary Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972873/ https://www.ncbi.nlm.nih.gov/pubmed/33328392 http://dx.doi.org/10.1292/jvms.20-0455 |
Ejemplares similares
-
The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015) -
Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM
por: Shirasu, Naoto, et al.
Publicado: (2012) -
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014) -
EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
por: Li, Dan, et al.
Publicado: (2023) -
Corrigendum to “Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM”
por: Shirasu, Naoto, et al.
Publicado: (2015)